The US Senate Finance Committee’s new legislative staffer for drug pricing, Anna Kaltenboeck, brings an interest in measuring drug value though cost per quality adjusted life year metrics and a skepticism about whether value-based contracting can control pricing.
The use of QALYs has gained attention in the US in recent years because it is used in cost effectiveness reviews by the Institute for Clinical and Economic Review